FDA Approves Igalmi for Agitation | Psychiatric News
WEBApr 25, 2022 · The Food and Drug Administration (FDA) in April approved a sublingual formulation of dexmedetomidine under the brand name of Igalmi for the treatment of agitation associated with schizophrenia or bipolar I or II disorder. Dexmedetomidine was previously approved in intravenous form for anesthesia.
Sublingual Dexmedetomidine as a Potential New Treatment for …
WEBEffect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation in Bipolar Disorder
Dexmedetomidine or Propofol for Sedation in Mechanically …
WEBFeb 2, 2021 · Guidelines currently recommend targeting light sedation with dexmedetomidine or propofol for adults receiving mechanical ventilation. Differences exist between these sedatives in arousability,...
BioXcel Therapeutics Announces FDA Approval of IGALMI™
WEBApr 6, 2022 · The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation ...
FDA Approves Dexmedetomidine for Agitation From Bipolar …
WEBApr 7, 2022 · The FDA has approved dexmedetomidine (Igalmi, BioXcel Therapeutics) sublingual film for the treatment of adults with agitation associated with bipolar disorders 1 and 2 and schizophrenia. Dexmedetomidine can be self-administered under the supervision of a health care provider.
Use of dexmedetomidine in critical-ill patients: is it time to look …
WEBAug 29, 2023 · Dexmedetomidine is an alpha-2 (ɑ2) adrenergic receptor and imidazoline type 2 receptor agonist that received Food and Drug Administration (FDA) approval in 1999 as a sedative and analgesic that also reduces stress, anxiety, and the risk of delirium in critically ill patients.
Sublingual Dexmedetomidine Promising for Acute Agitation …
WEBJul 20, 2020 · Dexmedetomidine is currently available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting. BXCL501 is an investigational proprietary...
Recent Advances in the Clinical Value and Potential of Dexmedetomidine
WEBDec 30, 2021 · Recent studies indicate several emerging clinical applications via different routes. We review recent data on dexmedetomidine studies, particularly exploring the varying routes of administration, experimental implications, clinical effects, and comparative advantages over other drugs.
Dexmedetomidine for agitation in dementia: Current data and …
WEB4 days ago · Dexmedetomidine has shown benefit for hospital delirium and for agitation in schizophrenia and bipolar disorder. However, there are no completed studies published on dexmedetomidine for agitation in dementia. Controlled studies with larger sample sizes are needed to assess the efficacy, safety, and the best route of administration for this drug ...
Efficacy and safety of dexmedetomidine for analgesia and
WEBOct 16, 2023 · Dexmedetomidine, a highly selective alpha-2-adrenoreceptor agonist, has piqued interest as a viable alternative for neonates, owing to its potential analgesic and neuroprotective attributes. We...
Skip to content